FindTrial
Sign In

Post-Transplant Cyclophosphamide

DRUG4 trials

Sponsors

Center for International Blood and Marrow Transplant Research, National Cancer Institute (NCI), Nantes University Hospital

Conditions

Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Myelogenous LeukemiaChronic Myeloid LeukemiaChronic Myelomonocytic Leukemia

Phase 2

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Active, not recruitingNCT04904588
Center for International Blood and Marrow Transplant ResearchAcute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia +5
Start: 2021-09-30End: 2026-12-01Target: 300Updated: 2026-03-18
Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency
Active, not recruitingNCT05907746
National Cancer Institute (NCI)GATA2, Immunodeficiency
Start: 2023-11-29End: 2028-07-31Updated: 2025-11-03
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Active, not recruitingNCT06001385
Center for International Blood and Marrow Transplant ResearchAcute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia +8
Start: 2023-12-08End: 2026-06-30Target: 313Updated: 2026-02-05
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
RecruitingNCT06252870
Nantes University HospitalGraft Versus Host Disease, Hematologic Malignancy
Start: 2024-07-18End: 2028-07-18Target: 82Updated: 2026-01-26

Related Papers

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study
Blood2025-11-03
Living the recovery: One-year qol outcomes for patients receiving ptcy gvhd prophylaxis on the access clinical trial
Blood2025-11-03
ACCELERATE: A platform protocol to investigate post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in patients with hematologic malignancies undergoing mismatched unrelated donor peripheral blood stem cell transplantation
Blood2025-11-03
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Journal of Clinical Oncology2025-06-1611 citations
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation
Blood Advances2025-02-0516 citations
OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Blood2024-11-052 citations
Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial
Blood2024-11-05
Post-transplant cyclophosphamide-based graft-<i>versus-</i>host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.
Journal of Clinical Oncology2024-06-014 citations
Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies
Blood2023-11-029 citations
Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Blood2022-11-155 citations